Source: Field of Cell and Gene Therapy

Based on the revenues of the world's largest pharmaceutical companies last year, Fierce Pharma has released a ranking of the world's top 20 pharmaceutical companies. Pfizer, Johnson & Johnson and Roche topped the list.

The world's top 20 pharmaceutical companies have all deployed cell and gene therapy (CGT) :

Pfizer

Revenue in 2022: $100.3 billion

2021 Revenue: $81.3 billion

Headquarters: New York City

Recommended reading article links:

1) $300 million! Pfizer introduced a new AAV capsid for the nervous system, and the licensor's share price jumped 17%

2) New development of macrophage therapy received $70 million investment from Pfizer

3) Pfizer DMD gene therapy Phase 3 clinical trial restarted, Solid Bio updated DMD gene therapy clinical research plan

4) More than $600 million to help develop new AAV gene therapies, Pfizer reached a partnership

Johnson & Johnson (JNJ)

2022 Revenue: $94.9 billion

2021 Revenue: $93.8 billion

Headquarters: New Brunswick, New Jersey

Recommended reading article links:

1) Johnson & Johnson/Legendary Bio suspend the launch of CAR T cell therapy in the UK

2) Eye gene therapy! Johnson & Johnson AAV-RPGR for X-linked Retinitis pigmentosa (XLRP) : Significantly improves vision!

Roche

2022 Revenue: $66.3 billion

2021 Revenue: $68.7 billion

Headquarters: Basel, Switzerland

Recommended reading article links:

1) Over $6 billion! Roche general purpose CAR T therapy

2) Over $1 billion! Roche has partnered with Avista to develop a next-generation AAV gene therapy vector for eye diseases

3) The world's first DMD gene therapy is coming to market, and FDA accepts BLA applications for DMD gene therapy from Roche and Sarepta

MSD

2022 Revenue: $59.3 billion

2021 Revenue: $48.7 billion

Headquarters: Kenilworth, New Jersey

Recommended reading article links:

1) Merck acquires Viralytics for $396 million to expand its oncolytic virus product line

2) Merck invested more than $3.5 billion to lay out circular RNA

AbbVie

2022 Revenue: $58.1 billion

2021 Revenue: $56.2 billion

Headquarters: North Chicago, Illinois

Recommended reading article links:

1) Gene therapy for Alzheimer's disease, AbbVie enters into R&D collaboration with Voyager Therapeutics

2) Over $660 million! Abbvie and Capsida collaborate on gene therapy for eye disease

Novartis

Revenue in 2022: $50.5 billion

2021 Revenue: $51.6 billion

Headquarters: Basel, Switzerland

Recommended reading article links:

1) Novartis releases new data: AAV gene therapy Zolgensma can be effective for up to 7.5 years

2) Novartis announces a new development strategy that prioritizes cell and gene therapy, radiation ligand therapy, and xRNA in terms of biologics and technology platforms

3) Novartis completes $1.5 billion acquisition of eye gene therapy company Gyroscope Therapeutics

4) Novartis acquired Arctos Medical, a gene therapy startup, and is optimistic about optogenetics technology

5) Two doses a year of powerful lipemia reduction, Novartis' first small interference nucleic acid therapy Leqvio® was approved by the FDA

Bristol Myers Squibb

2022 Revenue: $46.2 billion

2021 Revenue: $46.4 billion

Headquarters: New York City

Recommended reading article links:

1) New directions of cell therapy in the Gillette, AZ and BMS layout

2) USD 4 billion | Evotec and BMS continue to expand iPSC collaboration in the field of neurodegenerative diseases

3) BMS 'CD19 CAR-T is approved for marketing in the European Union

Sanofi

2022 Revenue: $45.2 billion

Revenue in 2021: $44.6 billion

Headquarters: Paris, France

Recommended reading article links:

1) 1.375 billion euros! Sanofi adds to the field of NK cell therapy

2) $400 million! Sanofi partners with RNA therapeutics to develop antibody-RNA coupling drugs

3) $1 billion: Sanofi works with Scribe to develop CAR-NK therapy with gene-editing technology

4) $3.2 billion! Sanofi acquires mRNA company Translate Bio

AstraZeneca

2022 Revenue: $44.4 billion

Revenue in 2021: $37.4 billion

Headquarters: Cambridge, United Kingdom

Recommended reading article links:

1) Astrazeneca's $320 million acquisition of Neogene, a bet on T-cell therapy

2) Up 638%! Astrazeneca acquires gene therapy company LogicBio

3) Astrazeneca acquires new T-cell immunotherapy for more than $1.2 billion

GSK

2022 Revenue: $36.2 billion

2021 Revenue: $46.9 billion

Headquarters: Cambridge, United Kingdom

Recommended reading article links:

1) GSK and Novartis obtain Bluebird lentivirus patents to develop gene therapy and CAR-T cell therapy

2) Why did GSK give up?

Takeda

2022 Revenue: $30 billion

2021 Revenue: $31.6 billion

Headquarters: Tokyo, Japan

Recommended reading article links:

1) Takeda cooperation, non-viral gene therapy is expected to enter the clinic

2) Takeda pipeline adjustment, return of gene therapy products worth more than $1 billion

Eli Lilly

2022 Revenue: $28.6 billion

2021 Revenue: $28.3 billion

Headquarters: Indianapolis, Indiana

Recommended reading article links:

1) Lilly and Capsida enter into strategic collaboration for AAV gene Therapy program for $740 million

2) $610 million! Eli Lilly acquires gene therapy company Akouos

3) Eli Lilly will build a $700 million Boston Gene therapy Research Center in addition to its $1 billion acquisition of Prevail Therapeutics

Gilead Sciences

2022 Revenue: $27.3 billion

2021 Revenue: $27.3 billion

Headquarters: Foster City, California

Recommended reading article links:

1) Summarize 45 gene therapy drugs that have been listed in the world

2) The CEO of Gilead's Kite Pharma is leaving

Bayer

2022 Revenue: $26.6 billion

2021 Revenue: $27.9 billion

Headquarters: Leverkusen, Germany

Recommended reading article links:

1) With nearly $300 million in Series B funding from Moderna and Bayer, gene editing technology company Metagenomi accelerated the development of gene editing products

2) The Bayer subsidiary was approved to conduct the Huntington gene therapy clinical trial

3) Bayer advances two pioneering cell and gene therapies for Parkinson's disease

Amgen

2022 Revenue: $26.3 billion

2021 Revenue: $26 billion

Headquarters: Thousand Oaks, California

Recommended reading article links:

1) Amgen teamed up with Advaxis to develop a novel tumor immunogene therapy ADXS-NEO

2) Amgen siRNA was clinically launched in China to reduce the risk of cardiovascular events

Boehringer Ingelheim

2022 Revenue: $25.3 billion

2021 Revenue: $24.2 billion

Headquarters: Ingelheim am Rhein, Germany

Recommended reading article links:

1) Boehringer Ingelheim collaborates with leading institutions to develop the first gene therapy for cystic fibrosis

2) Boehringer Ingelheim's $245 million acquisition of oncolytic virus gene Therapy

Novo Nordisk

2022 Revenue: $25 billion

2021 Revenue: $22.4 billion

Headquarters: Bagsvaerd, Denmark

Recommended reading article links:

1) Enter cell therapy! Novo Nordisk completes first patient dosing of HS-001, a cell therapy

2) Gene therapy company Freeline raises $120 million, Novo Nordisk Ventures joins

Moderna

2022 Revenue: $19.3 billion

2021 Revenue: $18.5 billion

Headquarters: Cambridge, Massachusetts

Recommended reading article links:

1) Moderna plans to collaborate with Life Edit to develop gene editing therapies for genetic diseases

2) Is Moderna's mRNA cancer vaccine near? The recurrence rate of advanced skin cancer is significantly reduced!

3) Close to $600 million, Moderna's first acquisition completed! Acquired OriCiro Genomics, a Japanese pioneer in cell-free DNA synthesis and amplification technology

4) Shares of mRNA drug company Moderna soared, pushing its market value past 130-year-old pharmaceutical giant Merck

Merck KGaA

2022 Revenue: $19.2 billion

2021 Revenue: $19.1 billion

Headquarters: Darmstadt, Germany

Recommended reading article links:

1) Merck increases its manufacturing capacity for commercial viral vectors and gene therapy products

2) Merck develops alternative CRISPR genome editing methods

BioNTech

2022 Revenue: $18.2 billion

2021 Revenue: $22.4 billion

Headquarters: Mainz, Germany

Recommended reading article links:

1) BioNTech enters into collaboration with Medigene to develop TCR cancer immune cell therapy

2) BioNTech launches mRNA malaria vaccine clinical trial